1. Scrip
  2. >>R&D
  3. >>Clinical Trials

CANTOS: Modest CV And Intriguing Lung Cancer Benefit With Canakinumab

 
• By Alexandra Shimmings

With CANTOS, Novartis's canakinumab has become the first investigational treatment to show that selectively targeting inflammation significantly reduces cardiovascular risk, albeit modestly, but with the added bonus of reducing lung cancer.

3d rendering Human Heart
• Source: Shutterstock

Reducing inflammation with Novartis AG's canakinumab (ACZ885) can lower the risk of lung cancer as well as cardiovascular disease, the full data from the CANTOS study show. Its researchers say the findings are a validation of the inflammation hypothesis in atherosclerosis, ushering in a "third era" in cardiovascular disease prevention, and at the same time open up new possibilities in cancer treatment.

In June, observers expressed surprise when the top-line data from the 10,000-patient CANTOS study proved positive, showing the anti-IL1β monoclonal...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.